CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
Cumberland Pharmaceuticals closed a $100M strategic transaction with Apotex, selling its commercial portfolio and related organization to pivot into a pure-play development-stage biopharma. The company funded a $1.50 per share special dividend with the proceeds while retaining its late-stage clinical pipeline, including four Phase 2 programs for ifetroban.
Key figures
- Revenue
- 166458
- Deal Value Usd
- 100000000
- Inventory funding
- $11 million
- Cash and equivalents
- 3862402
- Transaction proceeds
- $100 million
- Special dividend per share
- $1.50
- Loss from continuing operations
- 3100000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.